Compare Amgen, Inc. (AMGN) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Intuit Inc. — how do they compare? Amgen, Inc. trades at $359.22 (market cap $196.12B), while Intuit Inc. trades at $284.83 (market cap $75.21B). The key difference: Amgen, Inc. is far larger — about 2.6× Intuit Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | INTU | |
|---|---|---|
Market Cap | $196.12B | $75.21B |
Sector | Health | Technology |
52-Week High | $388.16 | $807.39 |
52-Week Low | $271.18 | $255.07 |
Enterprise Value | $241.41B | $73.67B |
Dividend Yield | 2.77% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Intuit (INTU) trades at $274.96, up 0.58% on the day, with a neutral technical signal and bearish moving averages. The stock is near its 52-week low of $275.00, reflecting recent pressure. Fundamentally, the company shows strong revenue growth, with 2025 revenue at $18.83B and net income of $3.87B, and has beaten earnings estimates in recent quarters. However, sentiment is mixed due to ongoing securities fraud investigations related to pricing issues, contributing to a significant stock decline over the past year.
The outlook for Intuit is cautiously optimistic, with robust fundamentals and a consensus analyst price target of $433.69 suggesting substantial upside. Key opportunities include continued earnings growth and AI-driven product expansion. Risks include legal uncertainties from fraud probes, competitive pressures, and potential regulatory scrutiny. Investors should weigh strong financial performance against near-term sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
